

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of Datang International Power Generation Co., Ltd..*



**大唐国际发电股份有限公司**

DATANG INTERNATIONAL POWER GENERATION CO., LTD.

*(a sino-foreign joint stock limited company incorporated in the People's Republic of China)*

**(Stock Code: 00991)**

## **WHITEWASH FOURTH SUPPLEMENTAL ANNOUNCEMENT**

**(I) CONNECTED TRANSACTION IN RESPECT OF THE  
PROPOSED A-SHARE ISSUANCE AND H-SHARE ISSUANCE**

**(II) SPECIFIC MANDATES**

**(III) APPLICATION FOR WHITEWASH WAIVER**

**(IV) POSTPONEMENT OF THE EGM AND THE CLASS MEETINGS**

**(V) EXTENSION OF CLOSURE OF H-SHARE REGISTER OF  
MEMBERS**

Reference is made to (i) the whitewash circular dated 9 February 2017 (the “**Whitewash Circular**”) published by Datang International Power Generation Co., Ltd. (the “**Company**”) in respect of, among other things, the A-Share Issuance, the H-Share Issuance and the Whitewash Waiver; (ii) the indicative announcement on convening the H-Share Class Meeting published by the Company on 10 March 2017; (iii) the whitewash supplemental circular dated 13 March 2017 (the “**Whitewash Supplemental Circular**”) in respect of the Whitewash Circular published by the Company; and (iv) the second supplemental notices and second revised proxy forms of the EGM, A-Share Class Meeting and H-Share Class Meeting published by the Company on 13 March 2017.

Unless otherwise defined, terms undefined herein shall have the meanings ascribed to them in the Whitewash Circular and/or the Whitewash Supplemental Circular.

## POSTPONEMENT OF THE EGM AND THE CLASS MEETINGS

As disclosed in the Whitewash Circular, the approval of SASAC is a condition to the coming into effect of the A-Share Subscription Agreement and the H-Share Subscription Agreement. In addition, pursuant to “Notice of the State-owned Assets Supervision and Administration Commission of the State Council on the Relevant Matters concerning Regulating the Issue of Exchangeable Bonds by a State-owned Shareholder of a Listed Company and the Issue of Securities by a State-controlled Listed Company” (《關於規範上市公司國有股東發行可交換公司債券及國有控股上市公司發行證券有關事項的通知》)(the “**Notice of the Relevant Matters**”) published by the State Council of the PRC and as advised by the PRC legal counsel of the Company, Hylands Law Firm, such approval of SASAC is a prerequisite for the convening of the EGM and the Class Meetings. In particular, the Notice of the Relevant Matters provides that the state-owned controlling shareholder of the state-controlled listed company should submit the relevant documents for approval by SASAC after the board meeting of the state-controlled listed company has approved the relevant issue of securities. If such SASAC approval may not be obtained before the relevant shareholders’ meeting convened to approve the relevant issue of securities, the state-owned controlling shareholder of the state-controlled listed company should propose for the listed company to postpone the shareholders’ meeting.

Following the board meeting of the Company held on 13 March 2017 to approve, among other things, the A-Share Subscription Second Supplemental Agreement and the H-Share Subscription Supplemental Agreement, CDC submitted the relevant documents in respect of the A-Share Issuance and the H-Share Issuance for approval by SASAC. However, based on its communication with SASAC, CDC understands that the relevant approval of SASAC may not be forthcoming before the scheduled date of the EGM and the Class Meetings on 28 March 2017. CDC, however, expects that such SASAC approval may be forthcoming on or before 31 March 2017 based on its previous communication with SASAC. As such, CDC has on 16 March 2017 proposed to the Company to postpone the EGM and the Class Meetings to 31 March 2017.

Accordingly, the Board hereby announces that the EGM, the A-Share Class Meeting and the H-Share Class Meeting scheduled to be held on 28 March 2017 (Tuesday) will be postponed to 31 March 2017 (Friday). The Company will publish the third supplemental notice and the third revised proxy form in respect of each of the postponed EGM, the A-Share Class Meeting and the H-Share Class Meeting on the same day as the publication of this announcement.

The notices of attendance for the EGM, A-Share Class Meeting and H-Share Class Meeting published by the Company on 25 January 2017 are still valid for the postponed EGM, A-Share Class Meeting and H-Share Class Meeting. The Company will publish any indicative announcement required by the Articles as and when appropriate. Completion of and return of any previously issued notices of attendance shall not preclude Shareholders from attending the EGM, the A-Share Class Meeting and/or the H-Share Class Meeting, as the case may be, and voting at these meetings.

## EXTENSION OF CLOSURE OF H-SHARE REGISTER OF MEMBERS

Due to the postponement of the EGM and the H-Share Class Meeting, in order to determine the Shareholders who will be entitled to attend and vote at the EGM and/or the H-Share Class Meeting, the original period of closure of the H-Share register of members of the Company as stated in the second supplemental notices of the EGM and the H-Share Class Meeting published on 13 March 2017 will be extended to the date of the postponed EGM and the H-Share Class Meeting.

By Order of the Board  
**Ying Xuejun**  
Company Secretary

Beijing, the PRC, 16 March 2017

*As at the date of this announcement, the Board comprises: (a) two executive Directors, namely Wang Xin and Ying Xuejun; (b) eight non-executive Directors, namely Chen Jinhang, Liu Chuandong, Liang Yongpan, Zhu Shaowen, Cao Xin, Zhao Xianguo, Liu Haixia and Guan Tiangang (Mdm.); and (c) five independent non-executive Directors, namely Liu Jizhen, Feng Genfu, Luo Zhongwei, Liu Huangsong and Jiang Fuxiu.*

*The Directors jointly and severally accept full responsibility for the accuracy of the information (other than those relating to CDC and parties acting in concert with it) contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.*

*As at the date of this announcement, the directors of CDC comprises Chen Jinhang, Chen Feihu, Sun Hanhong, Sun Xinguo, Chen Qiliang, Xia Donglin and Wang Wanchun.*

*The directors of CDC jointly and severally accept full responsibility for the accuracy of the information contained in this announcement relating to CDC and parties acting in concert with it, and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement the omission of which would make any statements in this announcement misleading.*